Crystal structure of PDE4D catalytic domain (tetramer) complexed with Rolipram - pdb ID = 1Q9M. Data from Emerald Biostructures are not yet released in the pdb.
The cyclic nucleotide phosphodiesterases (PDEs) are important regulators of signal transduction and selective inhibitors of the different subtypes have great clinical potential. PDE4 inhibitors are expected to be beneficial in the treatment of inflammatory and respiratory diseases such as asthma and COPD as well as CNS disorders including schizophrenia, depression, and Alzheimer’s disease but their potential has so far been limited by the incidence of side effects, particularly emesis. The emetic response is mediated in part by a brainstem noradrenergic pathway and, for non-CNS indications, can be reduced by limiting distribution of inhibitors to the brain. Active site directed PDE4 inhibitors completely inhibit enzyme activity at high concentrations but researchers at
Emerald Biostructures (formerly deCODE biostructures) have now identified allosteric small molecule modulators of PDE4 with reduced potential for side effects. The four PDE4 variants (PDE4A, B, C, and D) all contain signature regulatory domains called upstream conserved regions 1 and 2 (UCR1 and UCR2). UCR2 is needed for high-affinity binding of the PDE4 inhibitor rolipram and X-ray crystallographic structures revealed that small molecule inhibitors bind to UCR2, thereby controlling access to the active site. The team used the structural data together with supporting mutational data to design PDE4 allosteric modulators that only partially inhibit cAMP hydrolysis. The modulators were shown to be potent in cellular assays as well as
in vivo cognition tests and to have greatly reduced potential for emesis in several species. The authors hope that their work will lead to the identification of PDE4 modulators with reduced potential for emesis that can be used to treat disorders where brain distribution is needed. The study is published in the December 27
th advance online issue of
Nature Biotechnology.
Related posts:
- Potential New Drugs for Epilepsy Over 30% of the 50 million people who are affected by epilepsy do not have their seizures adequately controlled, even...
- Small Molecule Inhibitors of Kaposi’s Sarcoma Virus Protease Kaposi’s sarcoma (KS) is caused by Kaposi sarcoma herpes virus (KSHV) which is also known as human herpes virus 8...
- Structure of Aromatase Determined The majority (75-80%) of breast cancers are hormone-sensitive and their growth is stimulated by the hormones estrogen and progesterone. In...
- 2-AG – Not Such Eternal Bliss? The cannabinoid receptors, CB1 and CB2, were first identified as the receptors for the active components of Cannabis sativa. The...
- Potent Inhibitor of Insulin Degrading Enzyme Reported A new study from a Mayo Clinic-led research team has identified novel, potent inhibitors of insulin degrading enzyme (IDE). Despite...
Related posts brought to you by Yet Another Related Posts Plugin.
Email This Post
This entry was posted on Tuesday, January 5th, 2010 at 8:30 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)